Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis
Huseyin Naci(London School of Economics and Political Science), Christopher M. Booth(Queen's University), Xochitl Romo-Sandoval(London School of Economics and Political Science), Julian P. T. Higgins(University of Bristol), Bishal Gyawali(Ontario Institute for Cancer Research), Courtney Davis(King's College London), Jonathan A C Sterne(University of Bristol), Nicola Handley(King's College London), Jelena Savović(University Hospitals Bristol NHS Foundation Trust)
Cited by 242
Related Papers
Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis
|The Lancet|2018|3.5k
Graphical Tools for Network Meta-Analysis in STATA
|PLoS ONE|2013|2.5k
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19
|JAMA|2020|2.4k
CINeMA: An approach for assessing confidence in the results of a network meta-analysis
|PLoS Medicine|2020|1.7k